Risultati per: La gestione della costipazione indotta dagli oppioidi: il paradigma della qualità delle cure

A spiegarne le caratteristiche è il virologo Fabrizio Pregliasco

Coinvolge centri specializzati e atenei Bologna, Milano e Padova

Il rapporto del ministero della Salute evidenzia le differenze nella qualità dell’assistenza tra le Regioni italiane

Finanziato con oltre 3 mln dall’Ue, partecipa l’Irst di Meldola

Introduction
Despite universal access to government-funded direct-acting antivirals (DAAs) in 2016, the rate of hepatitis C treatment uptake in Australia has declined substantially. Most hepatitis C is related to injecting drug use; reducing the hepatitis C burden among people who inject drugs (PWID) is, therefore, paramount to reach hepatitis C elimination targets. Increasing DAA uptake by PWID is important for interrupting transmission and reducing incidence, as well as reducing morbidity and mortality and improving quality of life of PWID and meeting Australia’s hepatitis C elimination targets.

Methods and analysis
A cluster randomised cross-over trial will be conducted with three intervention arms and a control arm. Arm A will receive rapid hepatitis C virus (HCV) antibody testing; arm B will receive rapid HCV antibody and rapid RNA testing; arm C will receive rapid HCV antibody testing and same-day treatment initiation for HCV antibody-positive participants; the control arm will receive standard of care. The primary outcomes will be (a) the proportion of participants with HCV commencing treatment and (b) the proportion of participants with HCV achieving cure. Analyses will be conducted on an intention-to-treat basis with mixed-effects logistic regression models.

Ethics and dissemination
The study has been approved by the Alfred Ethics Committee (number HREC/64731/Alfred-2020-217547). Each participant will provide written informed consent. Reportable adverse events will be reported to the reviewing ethics committee. The findings will be presented at scientific conferences and published in peer-reviewed journals.

Trial registration number
NCT05016609.

Trial progression
The study commenced recruitment on 9 March 2022 and is expected to complete recruitment in December 2024.

Si punta a fronteggiare l’allerta caldo che in questi giorni è tornata ad allarmare sopratutto in alcune città dove si rischia di raggiungere i 40 gradi

Secondo il Crea Sanità solo il 55% degli italiani vive in Regioni con risultati soddisfacenti per la tutela della salute

Pochi sanno che da oltre 20 anni c’è una norma che “difende” i pazienti costretti ad attendere oltre ai tempi massimi previsti

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.